SC
IPXL

Samlyn Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Samlyn Capital’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-554,400
Closed -$8.93M – 155
2017
Q2 		$8.93M Sell
554,400
-13,600
-2% -$201K 0.22% 82
2017
Q1 		$7.18M Buy
+568,000
New +$6.86M 0.17% 105

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Samlyn Capital's IPXL Position: Q3 2017 in Review

Samlyn Capital sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 554,400 shares — an estimated $8.93M sold.

Samlyn Capital first reported a position in IPXL in Q1 2017 and held it in 2 quarters. The position peaked at $8.93M in Q2 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

  • Samlyn Capital reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
  • Samlyn Capital sold 554,400 Impax Laboratories, Inc. shares in Q3 2017, an estimated $8.93M.
  • Samlyn Capital first reported a position in Impax Laboratories, Inc. in Q1 2017 and held it in 2 quarters.
  • Samlyn Capital's Impax Laboratories, Inc. position peaked at $8.93M in Q2 2017.
  • 189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on Samlyn Capital's 13F filing for Q3 2017, filed 14 Nov 2017.